Quarry LP Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quarry LP reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 77.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224 shares of the biopharmaceutical company’s stock after selling 776 shares during the period. Quarry LP’s holdings in Alnylam Pharmaceuticals were worth $54,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after purchasing an additional 50,366 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after acquiring an additional 201,784 shares during the last quarter. Capital International Investors increased its holdings in Alnylam Pharmaceuticals by 1.8% during the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after acquiring an additional 64,560 shares in the last quarter. Capital Research Global Investors raised its position in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after acquiring an additional 214,908 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 9.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 1,111,111 shares of the biopharmaceutical company’s stock valued at $212,678,000 after purchasing an additional 100,000 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $267.99 on Friday. The stock has a 50-day simple moving average of $265.96 and a 200-day simple moving average of $206.48. The stock has a market capitalization of $33.90 billion, a P/E ratio of -100.00 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.21) earnings per share. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ALNY. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. TD Cowen boosted their price target on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, September 9th. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $279.14.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now owns 136 shares in the company, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 7,093 shares of the business’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,168,101. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 57,491 shares of company stock worth $15,446,733. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.